Two Chairs
Two Chairs matches patients with W-2 licensed therapists, backed by insurance networks and outcomes data.
On the record
Checkpoint: Next funding round decision (Series D, extension, or none) since no capital raised since April 2024
The call
Two Chairs has real outcomes data and payer relationships, but its slower W-2 model is being outscaled by better-funded marketplace rivals while its own growth and traffic slow.
Two Chairs is a therapy company that hires its own counselors as employees (rather than just connecting patients to freelancers) and works with insurance companies like Aetna and Kaiser. The downside is that paying full-time staff is expensive and limits how many patients the company can serve, while competitors like Headway have built networks of 60,000+ therapists and raised much more money to scale faster. The key question is whether Two Chairs can raise new funding soon and prove its patient outcomes are good enough to justify its higher costs, or whether it will need to merge with a bigger company or accept slower growth.
Why
01
AI pressure: AI therapy chatbots and AI-driven triage tools (e.g. Woebot-style entrants). AI chat tools could siphon low-acuity demand before referral, but licensed care for real diagnoses stays hard to automate for now. Could AI do the core job? Only partly.
02
Bigger players: Headway and Grow Therapy. Headway has 60k+ providers and a reported $2B+ valuation, Grow Therapy raised $88M from Sequoia the same month Two Chairs closed its Series C. Could a giant copy it? Yes, easily.
03
What protects it. Peer-reviewed outcomes data and W-2 clinician quality control give Two Chairs leverage in value-based payer contracts that marketplace rivals can't easily copy.
What would change this call
Two Chairs announces a new funding round (Series D or extension) within 12 months. Up-round signals renewed growth confidence; down-round or none signals capital strain.
Two Chairs' web traffic trend in coming quarterly reports. Continued decline beyond the reported 20% QoQ drop would confirm shrinking demand.
Reported change in Two Chairs' clinician headcount or reviews on employee sites like Glassdoor. Slower hiring or rising attrition would show the W-2 model straining under expansion.
Two Chairs' web traffic trend in coming quarterly reports. Continued decline beyond the reported 20% QoQ drop would confirm shrinking demand.
Reported change in Two Chairs' clinician headcount or reviews on employee sites like Glassdoor. Slower hiring or rising attrition would show the W-2 model straining under expansion.
Key numbers
- $72M Series C closed April 2024, no capital since
- 609 employees, only +4.5% YoY growth
- Web traffic down 20% quarter over quarter
Named risks
- No new funding round disclosed since April 2024, raising capital runway concerns.
- Employee reviews flag burnout and workload strain during rapid geographic expansion through mid-2025.
- W-2 clinician employment model is costlier to scale than 1099 marketplace models used by larger rivals.
- Revenue figures across third-party sources are wildly inconsistent, undermining financial transparency.
- Pending FDA guidance on AI-driven mental health tools, expected late 2026, could reshape competitive and regulatory landscape.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Headway | gaining on | 60,000+ provider network, reportedly valued above $2B as of 2026-03-20, vs Two Chairs' 600+ clinicians |
| Rula | gaining on | 21,000+ providers reported as of 2026-06-05, far exceeding Two Chairs' W-2 clinician count |
| Grow Therapy | gaining on | Raised $88M Series C led by Sequoia same month as Two Chairs' $72M round, April 2024 |
| Alma | contesting | 20,000+ clinician community, reportedly an acquisition target for Spring Health per 2026-05-22 analysis |
| Kaiser Permanente | contesting | Acts as both a payer partner and a vertically-integrated provider competing with Two Chairs, per 2026 site data |
Questions people ask
- Is Two Chairs profitable?
- Unverified. Revenue estimates from various data sources range wildly, from about $54M to $750M, with no consistent figure confirmed. Two Chairs has not disclosed profitability; its last funding round was a $72M Series C on April 16, 2024, with no new capital reported since.
- Has Two Chairs raised new funding recently?
- No new round has been publicly reported since its $72M Series C in equity and debt, led by Fifth Down Capital and Amplo, announced April 16, 2024. That is over two years without a disclosed capital raise as of mid-2026.
- Could AI replace Two Chairs' therapists?
- Not easily for core clinical delivery: no generative AI chatbot is FDA-cleared for mental health treatment as of late 2025, and Two Chairs relies on licensed W-2 clinicians. However, front-end functions like intake and therapist-matching are exposed to AI-native competitors.
- Who is Two Chairs' biggest competitor?
- Headway is the largest threat, with a 60,000+ provider network and a reported valuation above $2B as of March 2026, dwarfing Two Chairs' roughly 600+ W-2 clinicians reported in April 2025. Rula (21,000+ providers) and Grow Therapy also compete directly.
- Who owns Two Chairs?
- Two Chairs is privately held and venture-backed, founded in 2017 by Alex Katz in San Francisco. Investors include Amplo, Maveron, Goldcrest, and Fifth Down Capital, which led its $72M Series C announced April 16, 2024. It has not IPO'd.
- How does Two Chairs make money?
- Two Chairs bills through insurance in-network partnerships, primarily with Aetna, Kaiser Permanente, and Florida Blue, covering over 30 million lives as of December 2025. It launched psychiatry services in April 2025 to expand revenue beyond therapy alone.
Timeline
- 2025-12Published peer-reviewed study showing measurement-based care training improved outcomes 24% at scale
- 2025-04-30Launched psychiatry services with W-2 employed psychiatric providers integrated with therapy
- 2025-03-26Expanded in-network coverage to about 75% of U.S. population, targeting 22 states by June 2025
- 2025-01-14Published second peer-reviewed study claiming outcomes up to 2.5x better than standard care
- 2024-04-16Closed $72M Series C in equity and debt led by Fifth Down Capital and Amplo
- 2021-01Closed $21M Series B led by Amplo with Maveron and Goldcrest
- 2019-10-10Profiled with original pricing model of $149 consult and $180 per session
- 2017Founded by Alex Katz in San Francisco
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- This startup will match you with the right therapist (2019-10-10)
- Announcing our Series B
- Two Chairs raises $72M Series C in equity and debt to scale its therapist network (2024-04-16)
- Two Chairs - Headcount, Funding & Open Jobs (2026-07-08)
- Two Chairs - $42M Raised - Reviews & Alternatives (2026-07-01)
- Two Chairs, Mental health care, made for you
- Two Chairs Publishes First-of-Its-Kind Study...
- Two Chairs Expands Mental Health Services to 75% of the U.S. (2025-03-26)
- Announcing Our Series C
- Two Chairs Launches Psychiatry Services (2025-04-30)
- Two Chairs Company Growth, Stability & Outlook 2026 (2025-10-27)
- Two Chairs Study Shows Outcomes Up to 2.5× Better Than Standard Care (2025-01-14)